Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.
Hutchison China MediTech Ltd. (Chi-Med) has further strengthened its position for its first planned independent launch in China, after a second trial with anticancer surufatinib was stopped early after meeting its pre-defined primary endpoint of progression free survival (PFS).
The independent data monitoring committee of the Phase III SANET-p pivotal study in patients with advanced pancreatic neuroendocrine tumors (NET)...
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
